| Literature DB >> 29515912 |
Paula Cunnea1, Sally Gowers2, James E Moore2, Emmanuel Drakakis2, Martyn Boutelle2, Christina Fotopoulou1.
Abstract
Epithelial Ovarian cancer (EOC) is the fifth most common cause of cancer death in females in the UK. It has long been recognized to be a set of heterogeneous diseases, with high grade serous being the most common subtype. The majority of patients with EOC present at an advanced stage (FIGO III-IV), and have the largest risk for disease recurrence from which a high percentage will develop resistance to chemotherapy. Despite continual advances in diagnostics, imaging, surgery and treatment of EOC, there has been little variation in the survival rates for patients with EOC. In this review we will introduce novel bioengineering advances in modelling the lymphatic system and real-time tissue monitoring to improve the clinical and therapeutic outcome for patients with EOC. We discuss the advent of the non-invasive "liquid biopsy" in the surveillance of patients undergoing treatment and follow-up. Finally, we present new bioengineering advances for palliative care of patients to lessen symptoms of patients with ascites and improve quality of life.Entities:
Year: 2017 PMID： 29515912 PMCID： PMC5837061 DOI： 10.1088/2057-1739/aa5cf1
Source DB: PubMed Journal: Converg Sci Phys Oncol ISSN： 2057-1739